Merger Notification - Announcement according to § 10 Cartel Act
Theramex HQ UK Limited; bestimmte Rechte, Vermögenswerte und Titel zur Vermarktung von Duphaston und Femoston, von Viatris Inc., USA
BWB/Z-6354
On 25.08.2023 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Theramex HQ UK Limited, United Kingdom, intends to acquire certain rights, assets and titles to commercialise Duphaston and Femoston from Viatris Inc., United States.
Economic sector: Manufacture of basic pharmaceutical products and pharmaceutical preparations.
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 22.09.2023.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 23.09.2023 .